Literature DB >> 18423736

Residual tumor potentially left behind after local ablation therapy in prostate adenocarcinoma.

Ghil Suk Yoon1, Wenle Wang, Adeboye O Osunkoya, Zhaoli Lane, Alan W Partin, Jonathan I Epstein.   

Abstract

PURPOSE: We examined contralateral prostate cancer potentially left behind by focal therapy.
MATERIALS AND METHODS: We investigated 100 completely embedded radical prostatectomy specimens in which needle biopsy predicted limited disease (less than 3 positive cores, 50% or less involvement of any positive core, Gleason score 6 or less) and all positive needle cores were unilateral. Clinical stage was T1c in 85 and T2a in 15 cases with the palpable lesion on the positive biopsy side.
RESULTS: There was 1 positive core in 66 cases. On average 13.9% of each positive core was involved with tumor. The mean number of separate tumor nodules per radical prostatectomy was 2.9. In 65 radical prostatectomy specimens there was some tumor contralateral to the positive biopsy side. Total tumor volume in the radical prostatectomy contralateral to the positive biopsy side averaged 0.2 cm(3) (largest 1.3). In 23 cases contralateral tumor volume was greater than biopsy positive side tumor volume. There were 13 cases in which more than 0.5 cm(3) cancer was contralateral to the positive biopsy and 7 with predominantly anterior tumor. Volume contralateral to positive biopsy side could not be predicted by the number of positive cores (1 vs 2) or maximum percent of the core involved. Gleason pattern 4, extraprostatic extension or positive margins were seen contralateral to the positive biopsy side in 13, 1 and 2 cases, respectively.
CONCLUSIONS: In a highly selected population with limited unilateral biopsy cancer, tumor contralateral to the positive biopsy side at radical prostatectomy is typically small. However, 20% of radical prostatectomy specimens had some contralateral adverse pathology in terms of size, extraprostatic extension, grade or margins.

Entities:  

Mesh:

Year:  2008        PMID: 18423736      PMCID: PMC3353270          DOI: 10.1016/j.juro.2008.01.114

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  12 in total

1.  Increasing incidence of minimal residual cancer in radical prostatectomy specimens.

Authors:  J A DiGiuseppe; J Sauvageot; J I Epstein
Journal:  Am J Surg Pathol       Date:  1997-02       Impact factor: 6.394

2.  Carcinoma of the prostate: prognostic evaluation of certain pathologic features in 208 radical prostatectomies. Examined by the step-section technique.

Authors:  D P Byar; F K Mostofi
Journal:  Cancer       Date:  1972-07       Impact factor: 6.860

3.  Focal prostate cryoablation: initial results show cancer control and potency preservation.

Authors:  Duke K Bahn; Paul Silverman; Fred Lee; Robert Badalament; Eric D Bahn; John C Rewcastle
Journal:  J Endourol       Date:  2006-09       Impact factor: 2.942

4.  Predictive value of prostatic adenocarcinoma after a negative prostate biopsy.

Authors:  Paul C Park; Kien T Mai; Nicolas L D Roustan Delatour; Christopher Morash; Ilias Cagiannos
Journal:  BJU Int       Date:  2006-11       Impact factor: 5.588

5.  Predictability and significance of multifocal prostate cancer in the radical prostatectomy specimen.

Authors:  B Djavan; M Susani; B Bursa; A Basharkhah; R Simak; M Marberger
Journal:  Tech Urol       Date:  1999-09

6.  Characterization of minute adenocarcinomas of prostate at radical prostatectomy.

Authors:  Alexander M Truskinovsky; Harriete Sanderson; Jonathan I Epstein
Journal:  Urology       Date:  2004-10       Impact factor: 2.649

7.  Multiple cancers in the prostate. Morphologic features of clinically recognized versus incidental tumors.

Authors:  A Villers; J E McNeal; F S Freiha; T A Stamey
Journal:  Cancer       Date:  1992-11-01       Impact factor: 6.860

8.  The male lumpectomy: rationale for a cancer targeted approach for prostate cryoablation. A review.

Authors:  Gary Onik
Journal:  Technol Cancer Res Treat       Date:  2004-08

9.  Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer.

Authors:  J I Epstein; P C Walsh; M Carmichael; C B Brendler
Journal:  JAMA       Date:  1994-02-02       Impact factor: 56.272

10.  Prostate cancer laterality as a rationale of focal ablative therapy for the treatment of clinically localized prostate cancer.

Authors:  Vladimir Mouraviev; Janice M Mayes; Leon Sun; John F Madden; Judd W Moul; Thomas J Polascik
Journal:  Cancer       Date:  2007-08-15       Impact factor: 6.860

View more
  8 in total

1.  Best of the 2008 AUA Annual Meeting: Highlights from the 2008 Annual Meeting of the American Urological Association, May 17-22, 2008, Orlando, FL.

Authors:  Michael K Brawer; Danil V Makarov; Alan W Partin; Claus G Roehrborn; J Curtis Nickel; Shing-Hwa Lu; Naoki Yoshimura; Michael B Chancellor; Dean G Assimos
Journal:  Rev Urol       Date:  2008

2.  Amide proton transfer MR imaging of prostate cancer: a preliminary study.

Authors:  Guang Jia; Ronney Abaza; JoAnna D Williams; Debra L Zynger; Jinyuan Zhou; Zarine K Shah; Mitva Patel; Steffen Sammet; Lai Wei; Robert R Bahnson; Michael V Knopp
Journal:  J Magn Reson Imaging       Date:  2011-03       Impact factor: 4.813

3.  Re-evaluating the concept of "dominant/index tumor nodule" in multifocal prostate cancer.

Authors:  Cheng Cheng Huang; Fang-Ming Deng; Max X Kong; Qinhu Ren; Jonathan Melamed; Ming Zhou
Journal:  Virchows Arch       Date:  2014-03-12       Impact factor: 4.064

4.  Targeted focal therapy for prostate cancer: a review of the literature.

Authors:  Kathryn F Sullivan; E David Crawford
Journal:  Ther Adv Urol       Date:  2009-08

5.  A multidisciplinary approach to optimize primary prostate cancer biobanking.

Authors:  Peter Y Cai; Muhammad Asad; Michael A Augello; Laura Martin; Christopher Louie; Spyridon P Basourakos; Christopher D Gaffney; Jonathan Shoag; Jiangling Jenny Tu; Francesca Khani; Juan Miguel Mosquera; Massimo Loda; Douglas S Scherr; Christopher E Barbieri; Brian D Robinson
Journal:  Urol Oncol       Date:  2022-04-28       Impact factor: 2.954

Review 6.  Pathologic basis of focal therapy for early-stage prostate cancer.

Authors:  Vladimir Mouraviev; Janice M Mayes; Thomas J Polascik
Journal:  Nat Rev Urol       Date:  2009-04       Impact factor: 14.432

7.  Radical prostatectomy findings in patients in whom active surveillance of prostate cancer fails.

Authors:  Amy S Duffield; Thomas K Lee; Hiroshi Miyamoto; H Ballantine Carter; Jonathan I Epstein
Journal:  J Urol       Date:  2009-09-16       Impact factor: 7.450

Review 8.  A Review on Curability of Cancers: More Efforts for Novel Therapeutic Options Are Needed.

Authors:  Shuncong Wang; Yewei Liu; Yuanbo Feng; Jian Zhang; Johan Swinnen; Yue Li; Yicheng Ni
Journal:  Cancers (Basel)       Date:  2019-11-13       Impact factor: 6.639

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.